Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 16 October 2009, 12:08 HKT/SGT
Share:
    

Source: Eisai
Eisai Opens Regional Office in Bahrain

TOKYO, Oct 16, 2009 - (ACN Newswire) - Eisai Co., Ltd. announced today the opening of a regional office in Bahrain. The new office has been established as a branch of its Asian headquarters Eisai Asia Regional Services Pte. Ltd., in Singapore.

Eisai started doing business with the Middle East in the 1960's. It has since focused on the sale of products imported from Japan and up until now has been using local distributors to deliver these in-house developed pharmaceuticals and other products to patients.

This year Eisai launched Methycobal(R), a treatment for peripheral neuropathy, in Saudi Arabia, the biggest market in the Middle East, and the United Arab Emirates, and from next year it also hopes to receive approval to market other new products.

With this in mind, Eisai has been moving forward with preparations for the opening of the Bahrain Regional Office in order to establish an operational base in the area, as it looks towards full-scale business expansion in the Middle East and North Africa in the future. Eisai will commence operations in the region primarily through working with local distributors, while taking responsibility for marketing and registration of pharmaceutical products.

The Middle East and North Africa has a population of over 400 million, and is currently faced with an increase in lifestyle-related diseases such as obesity and diabetes as well as an aging society. Above all, diabetes is one of the issues affecting the region as it has the highest prevalence rate in the world. Eisai expects to make contributions to patients with diabetic neuropathy in the region through the availability of Methycobal.

Eisai currently operates globally in the United States, Europe and Asia. The Company sees the opening of the Bahrain Regional Office as an opportunity to make its in-house products available continuously as well as to actively introduce licensed products, which match the needs of the Middle East and North Africa, thereby contributing to addressing the needs and increasing the benefits of patients and their families in the region.

Outline of Bahrain Regional Office

Registered Company Name:  Eisai Asia Regional Services Pte. Ltd. 
Dated Established:        June 2009 
Location:                 AL-SEEF, Kingdom of Bahrain 
Director:                 Yasushi Okada 
Scope of Business:        Marketing and registration of 
                          pharmaceutical products



Contact:
PR Department
Eisai Co., Ltd.
+81-3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 16:33 HKT/SGT
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 1, 2024 12:56 HKT/SGT
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Oct 31, 2024 12:56 HKT/SGT
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
Oct 31, 2024 10:33 HKT/SGT
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Oct 17, 2024 19:01 HKT/SGT
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
Oct 17, 2024 14:59 HKT/SGT
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: